Revvity is showing a credible medium-term recovery, powered by software, reproductive health, and high-content imaging. But the stock already prices in much of the improvement, leaving limited upside at current levels.
Revvity (RVTY) offers a credible medium-term recovery story, but the stock already reflects much of the improvement. The company delivered Q1 2026 revenue of $711.1M, 3% organic growth, adjusted operating margin of 23.6%, and adjusted EPS of $1.06. Management raised the strategic quality of the business by announcing the planned divestiture of China immunodiagnostics, while software, reproductive health, and high-content imaging provide identifiable growth engines.
The investment case rests on three facts. First, Q1 organic growth was positive in both Life Sciences and Diagnostics, at 3% and 4%, respectively. Second, Signals software produced 40% year-over-year ARR growth and double-digit APV growth. Third, management expects 2026 pro forma adjusted EPS of $5.20 to $5.30 and adjusted operating margin of 28.4%.
The counterweight is valuation and leverage. At a quoted share price of $108.04, RVTY trades at 54.1x trailing earnings and 21.5x forward earnings, with $3.2B of debt against $919.9M of cash. The $112 fair value estimate supports a Hold for moderate-risk investors. A better entry price would provide more protection against execution risk, end-market softness, and the gap between adjusted earnings and GAAP earnings.
Revvity is a Waltham, Massachusetts-based health sciences company listed on the NYSE under RVTY. Founded in 1937 and formerly known as PerkinElmer, the company changed its name to Revvity in April 2023. It employs approximately 11,000 people and generated $2.9B of 2025 revenue.
The business combines research tools with diagnostics. Its Life Sciences segment serves pharmaceutical and biotechnology companies, academic and government laboratories, and research institutions with reagents, instruments, services, software, and workflow technologies. Its Diagnostics segment focuses on immunodiagnostics and reproductive health, including newborn screening, rare disease testing, and infectious disease applications.
The 2025 segment mix was nearly balanced. Life Sciences generated $1.43B, or 50.1% of company revenue, while Diagnostics generated $1.42B, or 49.9%. That balance gives RVTY more stability than a pure research-tools company, although it also creates exposure to distinct risk pools, including pharmaceutical budgets, academic funding, birth rates, reimbursement, and diagnostic policy.
Life Sciences generated Q1 2026 revenue of $362M, up 6% on a reported basis and 3% organically. Life Science Solutions posted low-single-digit organic growth in reagents and mid-single-digit growth in instrumentation. Signals software grew at a mid-single-digit organic rate, while APV and ARR growth were substantially stronger than the reported organic figure.
The customer split inside Life Sciences was constructive but still measured. Pharma and biotech sales grew at a low-single-digit organic rate, while academic and government sales grew at a mid-single-digit rate. Management also identified stronger demand for high-content screening tied to GLP-1 research, organ-on-chip development, and data generation for artificial intelligence models.
Diagnostics generated Q1 revenue of $349M, up 8% on a reported basis and 4% organically. Reproductive health grew at a double-digit organic rate, with newborn screening up at a low-double-digit rate. The Genomics England contract contributed more than initially expected as sample volumes ran slightly ahead of the original plan.
Immunodiagnostics remained the weaker piece. The business declined at a low-single-digit organic rate overall because meaningful declines in China offset stronger performance outside China. Management said the China business represented approximately 6% of total company revenue in the prior year and planned to divest it to remove a lower-growth, lower-margin operation.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The Opera Phenix OptIQ system is RVTY's flagship high-content screening platform. Management highlighted enhanced confocal imaging, advanced 3D cell analysis, and automated phenotypic profiling. Those capabilities align with complex disease modeling, precision medicine research, organ-on-chip work, and the validation demands created by AI-assisted drug discovery.
The product matters because an instrument sale can pull through reagents, consumables, services, and software. Q1 instrumentation growth in Life Science Solutions was in the mid-single digits, ahead of reagent growth. That mix supports a more durable revenue stream than a business dependent only on occasional capital-equipment purchases.
On the software side, Xynthetica is an AI models-as-a-service platform designed to connect computational capabilities with wet-lab research. BioDesign is a cloud-native molecular design platform for biologics development. LabGistics is planned as an AI-first drug discovery-to-development workflow offering. The three launches give Signals a concrete product pipeline rather than an abstract AI narrative.
That statement captures the commercial logic of the product portfolio. If AI increases the number of drug candidates and biological hypotheses, RVTY's instruments, assays, reagents, and software can sit in the validation loop. The opportunity is substantial, but revenue conversion will depend on customer adoption and the pace at which new software products become paid workloads.
RVTY's advantage is not based on one product alone. It combines an installed workflow position, proprietary technology, patents, diagnostic know-how, regulatory experience, and software integration. Customers can use the company across discovery, screening, genomic workflows, diagnosis, and data management, which creates opportunities for cross-selling and switching costs.
The software strategy is the clearest attempt to increase the quality of the mix. Management reported SaaS pipeline growth of 40% year over year and ARR growth above 30% in Q1. APV growth was in the double digits, even though reported software organic growth was in the mid-single digits. The difference reflects the timing of revenue recognition, but it also shows why recurring software metrics deserve attention.
RVTY also deployed multiple large language models across its global employee base. Management said the program accelerated software delivery and enabled initiatives that previously would not have been practical. Internal adoption can improve productivity, but it is not yet a substitute for evidence that the new commercial products will produce sustained revenue and margin expansion.
The moat is strongest where the company combines regulated diagnostic workflows with consumables and software. Regulatory clearance, clinical validation, proprietary assays, and customer process integration are harder to replicate than a standalone instrument feature. The 2025 10-K also identifies patents, trademarks, proprietary know-how, and licensed technology as important competitive assets.
The planned China immunodiagnostics divestiture is both a portfolio decision and an operating decision. Management said preserving that business would require localized manufacturing, supply chains, and regulatory capabilities. The company instead plans to direct capital and management time toward Life Sciences, reproductive health, and other areas with clearer growth trajectories.
The transaction has a long implementation timeline. RVTY signed a letter of intent with a local management-led buyer group and expects the transaction to close by the end of 2027, allowing time for manufacturing localization and regulatory approvals. Until completion, the business remains part of reported operations, while guidance excludes its financial impact on a pro forma basis.
Operational efficiency programs were in progress during Q1 and were scheduled to be substantially completed around midyear. Management expects the financial impact to become more visible in the second half of 2026 and to support further margin expansion in the first half of 2027. Q1 adjusted operating margin of 23.6% exceeded the 23.0% outlook, providing an initial execution marker.
The 2025 10-K identifies raw-material shortages, transportation disruptions, import and export restrictions, tariffs, and package delivery risks. These pressures matter because RVTY sells instruments and consumables across multiple regions. A broad product portfolio reduces dependence on one supplier, but the filings show that supply continuity remains an operating variable.
The global life science tools market was estimated at $164.5B in 2026 and projected to reach $230.1B by 2031, representing a 6.9% compound annual growth rate. A narrower life science instrumentation market was projected to grow at 6.5% from 2025 through 2031. These figures provide a favorable backdrop for RVTY's Life Sciences portfolio.
Growth is concentrating in areas relevant to RVTY. Next-generation sequencing was projected to grow at a 16.9% rate, while proteomics was projected to grow at 13.1%. Software, automation, multi-omics, and precision medicine also support greater use of instruments, assays, data platforms, and consumables.
The market backdrop is better than RVTY's 2026 pro forma organic growth guide of 3% to 4%. That gap does not automatically signal a problem because RVTY has exposure to mature diagnostics categories, regional policy pressure, and customer budget cycles. It does show that execution must improve for the company to capture more of the industry's underlying expansion.
Outsourcing is another favorable market force. Pharma and biotech companies are using external analytical services to control fixed costs and access specialized expertise. Diagnostic laboratories are also adopting more regulated, validation-heavy workflows. RVTY's combination of instruments, reagents, software, and diagnostics gives it several ways to participate in those spending shifts.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
RVTY serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, physicians, and government agencies. This customer diversity is important because spending cycles do not move in lockstep. Pharma and biotech grew at a low-single-digit organic rate in Q1, while academic and government customers grew at a mid-single-digit rate.
The Life Sciences customer base is most sensitive to research budgets, biotech financing, instrument replacement cycles, and pharmaceutical development activity. Management described customer behavior as measured while budgets were being worked through, which explains why Q1 growth was positive but restrained.
Diagnostics customers have a different demand profile. Newborn screening, reproductive health, and rare disease testing serve clinical and public-health needs. Q1 reproductive health growth at a double-digit organic rate, including low-double-digit newborn screening growth, demonstrates the defensive value of those workflows even as global birth rates remain challenging.
Signals software serves scientific users who need data management, molecular design, and AI-enabled research workflows. The company's materials describe software reaching more than 2 million scientists. If BioDesign, Xynthetica, and LabGistics gain adoption across existing accounts, RVTY can expand revenue per customer without relying solely on new instrument placements.
RVTY competes with companies that are much larger and with specialized niche providers. Thermo Fisher Scientific reported more than $45B of annual revenue and competes across reagents, instruments, laboratory services, and pharmaceutical services. Danaher competes in biotechnology, diagnostics, and life sciences. Agilent reported $6.95B of fiscal 2025 revenue and competes in analytical instruments and applied markets.
Other relevant competitors include Waters, Bio-Techne, QIAGEN, Illumina, Sartorius, Bruker, Shimadzu, and Merck KGaA. The competitive set changes by product. Thermo Fisher, Danaher, Bio-Techne, and QIAGEN are particularly relevant to reagents and workflow tools, while Illumina matters more in genomics and sequencing-related applications.
RVTY's size is a disadvantage in purchasing power and R&D scale, but its specialized portfolio can compete through product differentiation, workflow integration, service, reliability, and regulatory expertise. The Opera Phenix OptIQ system and Signals software are examples of products that compete on workflow capability rather than on simple unit price.
The competitive risk is real. The 2025 10-K states that rivals may have greater financial, technical, manufacturing, regulatory, and distribution resources. RVTY must continue launching products on schedule and protect its installed base from broader platforms that can bundle multiple tools into one customer relationship.
China is the clearest geopolitical pressure point. Management said policy-induced headwinds have hurt demand and pricing in Chinese diagnostics and expects those conditions to continue over the medium term. China declined at a double-digit rate overall in Q1, while Europe grew at a double-digit rate and the Americas grew at a low-single-digit rate.
The divestiture reduces direct exposure to the most challenged Chinese diagnostic operation, but it does not remove all China risk. RVTY's Life Sciences business in China remained larger than the immunodiagnostics business being divested and continued to perform well, particularly in reagents. Management expects that business to continue growing with the right products and policy conditions.
Foreign exchange contributed approximately 3% to Q1 reported growth, while the full-year 2026 assumption was reduced to a 50-basis-point benefit from a prior 100-basis-point assumption. Tariffs and trade restrictions also affected the Q1 margin outlook. These factors make reported revenue less informative than organic growth and create a direct risk to gross margin.
Academic and government spending showed a mid-single-digit improvement in Q1, including positive U.S. growth for the first time since Q2 2023. Research budgets remain tied to policy decisions, so the improvement supports the recovery thesis without removing budget sensitivity. Global birth-rate trends create a separate pressure on newborn screening volumes, although Q1 newborn screening growth remained in the low double digits.
$3.2B of debt versus $919.9M of cash leaves Revvity with meaningful leverage, even after the company’s planned China immunodiagnostics divestiture.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 revenue rose to $711.1M with a 23.6% adjusted operating margin and $1.06 of adjusted EPS, showing solid operating leverage.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is guiding to 2026 pro forma adjusted EPS of $5.20 to $5.30 and a 28.4% adjusted operating margin, implying further margin expansion.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $108.04, Revvity trades at 54.1x trailing earnings and 21.5x forward earnings, leaving little room for disappointment.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $112 fair value sits just above the current share price, supporting a Hold rather than a more aggressive rating.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revvity (RVTY) is moving in the right direction operationally. Q1 2026 produced $711.1M of revenue, 3% organic growth, 23.6% adjusted operating margin, and $1.06 of adjusted EPS. Life Sciences and Diagnostics both grew organically, reproductive health delivered double-digit growth, and Signals produced software metrics that are stronger than the headline segment rate.
The China immunodiagnostics divestiture is the most important portfolio action. It lowers exposure to a policy-damaged business, improves the expected growth and margin mix, and allows capital to move toward higher-return opportunities. The tradeoff is a long closing timeline and continued exposure to China through Life Sciences.
The stock is not a bargain at $108.04, but neither is it detached from the earnings recovery. The forward P/E of 21.5x, PEG ratio of 0.7, 5.2% FCF yield, and analyst target of $117.13 support a balanced view. The Hold recommendation reflects an improving business at a price that leaves limited room for operational disappointment.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Revvity, Inc. (RVTY) rises after a clean Q1 earnings beat, but the real story is in the details: stronger-than-expected margins, steady organic growth, and a guidance reset tied to a strategic China exit rather than core business weakness. Here’s what the numbers and outlook really mean.
Revvity is a balanced life sciences and diagnostics operator with improving earnings, solid cash flow, and a growing software mix. The stock looks more like a recovery rerating than a breakout, but valuation is reasonable if forward EPS delivers.
Revvity, Inc. (RVTY) rises 7.0% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook signals.